Hydroxycarbamide

Antimetabolite — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Hydroxycarbamide is a drug in the Antimetabolite class catalogued in DrugCentral. It was first approved by the FDA in 1967. DrugCentral lists 5 molecular targets, including CA9, CA2 and CA5A. Recorded indications include Chronic myeloid leukemia, Hb SS disease, Hemoglobin SS disease with crisis and Malignant melanoma.

• Drug class: Antimetabolite.
• Molecular targets: CA9, CA2, CA5A and RRM1 (5 listed in DrugCentral).
• Indications: Chronic myeloid leukemia, Hb SS disease, Hemoglobin SS disease with crisis, Malignant melanoma and Malignant tumor of head and/or neck and others.
• ATC code: L01XX05 (Other antineoplastic agents).
• Molecular formula: CH4N2O2; molecular weight 76.06 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Chronic myeloid leukemia
• Hb SS disease
• Hemoglobin SS disease with crisis
• Malignant melanoma
• Malignant tumor of head and/or neck
• Malignant tumor of ovary
• Sickling disorder due to hemoglobin S

Off-label uses (2)

• Essential thrombocythemia
• Polycythemia vera

Contraindications (9)

• Anemia
• Breastfeeding (mother)
• Kidney disease
• Leukopenia
• Postirradiation Erythema
• Pregnancy, function
• Severe Bone Marrow Depression
• Thrombocytopenic disorder
• Vasculitis of the skin

Mechanism & targets

• Established pharmacologic class: Antimetabolite

Molecular targets (5)

Target	Gene	Action	Activity
Carbonic anhydrase 9	CA9	unknown	Ki 4.64
Carbonic anhydrase 2	CA2	unknown	Ki 4.55
Carbonic anhydrase 5A, mitochondrial	CA5A	unknown	Ki 4.51
Ribonucleoside-diphosphate reductase large subunit	RRM1	inhibitor	—
Ribonucleoside-diphosphate reductase subunit M2	RRM2	inhibitor	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2019-07-01	EMA	—	NOVA LABORATORIES IRELAND LIMITED
1967-12-07	FDA	—	BRISTOL MYERS SQUIBB

ATC classification

ATC code	Therapeutic hierarchy
L01XX05	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Sickle cell anaemia with crisis	1677.8
Platelet count increased	625.8
Splenomegaly	592.8
Myelofibrosis	532.5
Acute myeloid leukaemia	466.9
Acute chest syndrome	461.7
White blood cell count increased	433.7
Anaemia	425.1
Haemoglobin decreased	355.0
Differentiation syndrome	343.0
Thrombocytopenia	305.9
Leukocytosis	288.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Hydroxycarbamide is on its molecule page.

• Molecular formula: CH₄N₂O₂
• Molecular weight: 76.06 g/mol
• CAS number: —
• InChIKey: VSNHCAURESNICA-UHFFFAOYSA-N
• PubChem CID: 3657

NC(=O)NO

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Hydroxycarbamide used for?

DrugCentral lists the following indications for Hydroxycarbamide: Chronic myeloid leukemia, Hb SS disease, Hemoglobin SS disease with crisis, Malignant melanoma, Malignant tumor of head and/or neck, Malignant tumor of ovary and Sickling disorder due to hemoglobin S.

How does Hydroxycarbamide work?

Its molecular targets in DrugCentral include CA9, CA2, CA5A and RRM1 (inhibitor).

When was Hydroxycarbamide first approved?

Hydroxycarbamide was first approved by the FDA in 1967.

What drug class does Hydroxycarbamide belong to?

Hydroxycarbamide is in the Antimetabolite class.

What is the chemical formula of Hydroxycarbamide?

Hydroxycarbamide has the molecular formula CH4N2O2 and a molecular weight of 76.06 g/mol.

Sources

• DrugCentral drug card 1399 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL467 — compound record and bioactivity
• PubChem CID 3657 — chemical identifiers
• DrugBank DB01005 — drug record
• FDA UNII X6Q56QN5QC — substance identity
• DailyMed: FDA labels for Hydroxycarbamide — current prescribing information (label search)
• UniProt Q16790 (CA9) — target protein
• UniProt P00918 (CA2) — target protein
• UniProt P35218 (CA5A) — target protein
• UniProt P23921 (RRM1) — target protein
• UniProt P31350 (RRM2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.